Beam Therapeutics Inc. - Common Stock (BEAM)

Nicole Verdun and Rachael Anatol were placed on administration leave without explanation.

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments.

The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly.

Beam Therapeutics shared updated BEAM-302 trial data in AATD and plans U.S. site activation following FDA clearance of its IND

Cathie Wood-led Ark Invest made notable trades, buying IRDM, BEAM, PACB, ABSI and selling ILMN, RPTX, AMGN, VEEV.

Beam Therapeutics reports Phase 1/2 trial data showing BEAM-302's potential in AATD treatment, with dose-dependent mutation correction and sustained effects.

Cathie Wood-led Ark Invest made trades involving IRDM, TWST, PD, BEAM, ROKU, and IBTA.

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future.

Beam Therapeutics unveiled BEAM-101 trial data at ASH, showing improved outcomes in sickle cell patients and promising preclinical BEAM-103 results.